Torrent Pharma strengthens anti-diabetes portfolio with acquisition of three brands from Boehringer

India is often referred to as the diabetes capital of the world, and this patient base is expected to increase to almost 12.5 crore patients by 2045.

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

India's seventh largest drug company Torrent Pharma has decided to strengthen its anti-diabetes portfolio with the acquisition of three brands from Germany's Boehringer Ingelheim GmbH, the company said on December 4.

"The acquisition is expected to be completed in March 2025. Torrent has been marketing these brands since 2022 as part of an existing co-marketing agreement with Boehringer Ingelheim India," the company said in a statement.

The market for Empagliflozin, a sodium glucose co-transporter-2 (SGLT-2) inhibitor, which indicates glycemic control in type 2 diabetes is valued at Rs 3,235 crore, growing faster than the diabetes market at 25% CAGR. The agreement is for acquisition of the brands - Cospiaq, Cospiaq Met and Xilingio from Boehringer Ingelheim, all of which have Empagliflozin as a constituent.

Aman Mehta, Director, Torrent Pharma said, “As we continue to strengthen our diabetes care portfolio, we will ensure continued access to the treatment for patients whilst building on our presence in the Oral Anti Diabetic market”.

The International Diabetes Federation says India has the second largest number of diabetics in the world, at an estimated 7.42 crore adults (20-79 years age group) as of 2021. The country is often referred to as the diabetes capital of the world, and this patient base is expected to increase to almost 12.5 crore patients by 2045.

As per another estimate, India's diabetes medication market is valued at Rs 19,912 crore, growing at 7.7% CAGR over last 4 years.